Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126679032 | 12667903 | 2 | F | 20160908 | 20160819 | 20160914 | EXP | DE-PFIZER INC-2016382853 | PFIZER | ILLERHAUS, GERALD. HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: A PROSPECTIVE, SINGLE-ARM, PHASE 2 TRIAL. THE LANCET HAEMATOLOGY. 2016;3(8):E388-97 | 0.00 | Y | 0.00000 | 20160914 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126679032 | 12667903 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 8000 MG/M2, (DAYS 1, 11, 21, AND 31) | 11719 | 8000 | MG/M**2 | ||||||||
| 126679032 | 12667903 | 2 | SS | CYTARABINE. | CYTARABINE | 1 | 3 G/M2 (DAYS 2 AND 3) | 0 | |||||||||||
| 126679032 | 12667903 | 3 | SS | RITUXIMAB | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 375 MG/M2, CYCLIC (7 DAYS BEFORE FIRST HIGH-DOSE METHOTREXATE COURSE AND DAYS 0, 10, 20, AND 30) | 0 | 375 | MG/M**2 | ||||||||
| 126679032 | 12667903 | 4 | SS | RITUXIMAB | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 375 MG/M2, CYCLIC (DAY 1) | 0 | 375 | MG/M**2 | ||||||||
| 126679032 | 12667903 | 5 | SS | THIOTEPA. | THIOTEPA | 1 | 40 MG/M2, CYCLIC (DAY 3) | 0 | 40 | MG/M**2 | |||||||||
| 126679032 | 12667903 | 6 | SS | THIOTEPA. | THIOTEPA | 1 | 5 MG/KG, UNK (2 ? 5 MG/KG [DAYS 3 AND 4]) | 0 | 5 | MG/KG | |||||||||
| 126679032 | 12667903 | 7 | SS | CARMUSTINE | CARMUSTINE | 1 | 400 MG/M2, (DAY 2) | 0 | 400 | MG/M**2 | |||||||||
| 126679032 | 12667903 | 8 | C | FOLINIC ACID | LEUCOVORIN | 1 | 15 MG/M2 AT LEAST EVERY 6 HOURS | 0 | 15 | MG/M**2 | |||||||||
| 126679032 | 12667903 | 9 | C | FILGRASTIM | FILGRASTIM | 1 | 300 UG, CYCLIC (DAYS 6-10 WITH 21 DAY BREAK) | 0 | 300 | UG | |||||||||
| 126679032 | 12667903 | 10 | C | PEGFILGRASTIM | PEGFILGRASTIM | 1 | Subcutaneous | 6 MG, (4 DAYS AFTER AUTOLOGOUS STEM CELL REINFUSION) | 0 | 6 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126679032 | 12667903 | 1 | Lymphoma |
| 126679032 | 12667903 | 2 | Lymphoma |
| 126679032 | 12667903 | 3 | Lymphoma |
| 126679032 | 12667903 | 5 | Lymphoma |
| 126679032 | 12667903 | 7 | Lymphoma |
| 126679032 | 12667903 | 8 | Supportive care |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126679032 | 12667903 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126679032 | 12667903 | Pneumonia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |